Stocks Health care SUPN
NASDAQ · Health careSupernus Pharmaceuticals, Inc. (SUPN)
Supernus Pharmaceuticals, Inc. brought in $830.4M of revenue over the twelve months to June 30, 2026, up 24.9% from a year earlier. It posted a net loss of $109.9M. Operating cash flow minus capital spending left $46M of free cash flow in fiscal 2025. At June 30, 2026 it held $180M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 3, 2026.
What Supernus Pharmaceuticals, Inc. does
Supernus Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SUPN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $719M | -$38.6M | -$0.68 | $46M |
| 2024 | $661.8M | $73.9M | $1.32 | $171.2M |
| 2024 | $607.5M | $1.3M | $0.02 | $110.5M |
| 2022 | $667.2M | $60.7M | $1.04 | $116.4M |
| 2021 | $579.8M | $53.4M | $0.98 | n/a |
| 2020 | $520.4M | $127M | $2.36 | $135M |
Latest SEC filings
What Supernus Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 11, 2026Merger proxy statement DEFM14A
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- August 3, 2026Additional proxy material DEFA14A
- August 3, 2026Form 425 filing 425
- August 3, 2026Other event 8-K
- August 3, 2026Additional proxy material DEFA14A
- August 3, 2026Form 425 filing 425
- August 3, 2026Other event 8-K
- August 3, 2026Quarterly report 10-Q · period to June 30, 2026
- August 3, 2026
Questions about SUPN
What does Supernus Pharmaceuticals, Inc. do?
Supernus Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SUPN.
Is Supernus Pharmaceuticals, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $109.9M on revenue of $830.4M.
How much revenue does Supernus Pharmaceuticals, Inc. make?
Over the twelve months to June 30, 2026 Supernus Pharmaceuticals, Inc. reported revenue of $830.4M. That is 24.9% more than a year earlier.
When did Supernus Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 3, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the merger proxy statement from September 11, 2026.
Similar companies
Follow SUPN
Get an email when Supernus Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow SUPN: get an email when it filesWhere the numbers come from
Financial figures are the values Supernus Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.